Abstract
With the recent development in molecular genetics, the WHO classification of CNS tumors was revised in 2016. The new WHO classification made a paradigm shift from traditional histologic classification to molecular classification. In particular, integrated diagnoses that combined morphologic and molecular information were introduced for diffuse gliomas and embryonal tumors. The new classification is expected to result in more accurate diagnosis, appropriate therapeutic strategy, precise prediction of prognosis, etc. Practical efforts have already been started at the clinical sites to adapt to the new classification.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
